Skip to main content
Premium Trial:

Request an Annual Quote

Myriad's Shares Hit 52-Week Low

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slumped to a 52-week low earlier today, after the firm's stock was downgraded by investment bank JP Morgan.

Myriad fell to as low as $14.26 before rebounding slightly in the afternoon to $14.75 — still down 6 percent on the day.

JP Morgan downgraded Myriad's stock to "neutral" from "overweight" and cut its price target to $18 from $28.

Myriad's shares were down sharply — around 43 percent — in the first half of 2010, as its stock came under pressure after a federal District Court in late March declared Myriad's BRCA gene patents invalid. A little more than a month later, Myriad posted first-quarter revenues that fell well short of analysts' consensus estimate.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.